Spyre Therapeutics (NASDAQ:SYRE) Announces Quarterly Earnings Results, Beats Estimates By $0.40 EPS

Spyre Therapeutics (NASDAQ:SYRE) issued its quarterly earnings results on Tuesday. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.40, FiscalAI reports.

Spyre Therapeutics Stock Down 0.5%

SYRE traded down $0.50 during trading on Thursday, hitting $103.85. The company’s stock had a trading volume of 195,799 shares, compared to its average volume of 1,083,965. The firm’s 50 day moving average price is $89.91 and its two-hundred day moving average price is $64.66. Spyre Therapeutics has a 12 month low of $14.51 and a 12 month high of $108.14. The stock has a market capitalization of $9.13 billion, a price-to-earnings ratio of -53.24 and a beta of 3.03.

Insiders Place Their Bets

In other news, CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $95.51, for a total value of $1,432,650.00. Following the completion of the sale, the chief executive officer directly owned 567,540 shares in the company, valued at approximately $54,205,745.40. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 7,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $95.57, for a total transaction of $716,775.00. Following the transaction, the chief financial officer owned 97,994 shares in the company, valued at approximately $9,365,286.58. This trade represents a 7.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 199,167 shares of company stock valued at $16,327,042. 15.69% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Spyre Therapeutics

A number of large investors have recently modified their holdings of the stock. Janus Henderson Group PLC increased its stake in shares of Spyre Therapeutics by 13,969.3% in the 4th quarter. Janus Henderson Group PLC now owns 1,829,009 shares of the company’s stock valued at $59,918,000 after buying an additional 1,816,009 shares during the period. RA Capital Management L.P. acquired a new position in shares of Spyre Therapeutics during the fourth quarter valued at $53,124,000. Remedium Capital Partners LLC bought a new position in Spyre Therapeutics in the fourth quarter valued at about $47,706,000. TCG Crossover Management LLC bought a new position in Spyre Therapeutics in the third quarter valued at about $18,446,000. Finally, Price T Rowe Associates Inc. MD increased its position in Spyre Therapeutics by 158.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,601,882 shares of the company’s stock worth $52,479,000 after purchasing an additional 981,262 shares during the period. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SYRE has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spyre Therapeutics in a report on Thursday, June 4th. Wells Fargo & Company lifted their price target on shares of Spyre Therapeutics from $90.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday. Mizuho raised their price objective on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Citigroup upped their target price on shares of Spyre Therapeutics from $64.00 to $97.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Jefferies Financial Group raised their price target on shares of Spyre Therapeutics from $47.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Spyre Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $110.15.

Spyre Therapeutics News Roundup

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Spyre reported a second-quarter loss of $0.36 per share, narrower than the $0.76 loss analysts expected. The earnings beat improved sentiment by suggesting better-than-anticipated expense management. SYRE’s Q2 Loss Narrower Than Expected, Pipeline Progresses
• Positive Sentiment: The biotechnology company highlighted progress in its Phase 2 pipeline and upcoming clinical data readouts. These milestones are key potential catalysts because Spyre remains a clinical-stage company without near-term product revenue. Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Wedbush raised its price target from $100 to $130 and maintained an “Outperform” rating. Guggenheim also lifted its target to $130 and retained a “Buy” rating, reinforcing expectations for additional pipeline-driven upside. Analyst price-target updates
• Neutral Sentiment: SYRE reached a new one-year high following the earnings beat, indicating strong momentum but also leaving the stock more sensitive to profit-taking and clinical-news volatility. Spyre Therapeutics Hits New 1-Year High Following Earnings Beat
• Negative Sentiment: CEO Cameron Turtle sold 15,000 shares and CFO Scott Burrows sold 7,500 shares at approximately $95.51–$95.57. Both transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing the bearish signal, and both executives continue to hold substantial positions. Spyre Therapeutics Insider Trading

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.